Core Viewpoint - Nike (NKE) is expected to report a significant decline in quarterly earnings and revenues, with earnings per share forecasted at $0.28, a 71.4% decrease year-over-year, and revenues projected at $11.12 billion, reflecting a 10.6% decline [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been revised upward by 3.4%, indicating analysts' reassessment of their initial forecasts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts estimate 'Revenue- Converse' at $457.15 million, down 7.7% from the previous year [5]. - 'Revenue- Global Brand Divisions' is projected at $9.79 million, up 8.8% year-over-year [5]. - 'Revenue- Equipment' is expected to reach $492.96 million, reflecting a 1.2% increase year-over-year [5]. Geographic Revenue Insights - 'Revenue- Footwear' is anticipated to be $7.07 billion, down 13.4% year-over-year [6]. - 'Geographic Revenue- North America' is projected at $4.45 billion, a decrease of 12.3% from the prior year [6]. - 'Geographic Revenue- Asia Pacific & Latin America' is expected to be $1.54 billion, down 6.5% year-over-year [6]. - 'Geographic Revenue- Europe, Middle East and Africa' is forecasted at $2.80 billion, reflecting a 10.9% decline [7]. - 'Geographic Revenue- Greater China' is estimated at $1.81 billion, down 13.2% year-over-year [7]. - The total 'Geographic Revenue- Nike Brand' is projected at $10.61 billion, indicating an 11.2% decrease from the previous year [8]. Performance Comparison - Nike shares have returned -1.9% over the past month, outperforming the Zacks S&P 500 composite, which declined by 7.7% [9].

Core Viewpoint - General Mills is expected to report a decline in quarterly earnings and revenues, with analysts predicting earnings of $0.95 per share, an 18.8% decrease year-over-year, and revenues of $4.96 billion, a 2.8% decrease compared to the same period last year [1]. Earnings Estimates - The consensus EPS estimate for the quarter has been adjusted downward by 2.4% over the past 30 days, indicating a reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical research shows a strong correlation between earnings estimate revisions and short-term stock performance [3]. Key Metrics Forecast - Analysts forecast 'Net Sales- North America Foodservice' to reach $576.36 million, reflecting a year-over-year increase of 4.5% [5]. - 'Net Sales- International' is expected to be $686.85 million, indicating a 1% year-over-year increase [5]. - 'Net Sales- North America Pet' is projected at $636.11 million, showing a 1.9% increase year-over-year [5]. - 'Net Sales- North America Retail' is anticipated to be $3.07 billion, representing a 5.3% decrease from the previous year [6]. Operating Profit Estimates - 'Operating Profit- North America Retail' is expected to be $671.69 million, down from $752.20 million year-over-year [6]. - 'Operating Profit- International' is projected at $20.31 million, an increase from $18.20 million in the same quarter last year [7]. - 'Operating Profit- North America Pet' is forecasted to reach $131.74 million, compared to $128.30 million in the same quarter of the previous year [7]. - 'Operating Profit- North America Foodservice' is expected to be $88.74 million, up from $81.70 million in the same quarter last year [8]. Stock Performance - General Mills shares have increased by 0.5% over the past month, contrasting with a -9.6% change in the Zacks S&P 500 composite [9]. - The company holds a Zacks Rank 3 (Hold), indicating it is expected to closely follow overall market performance in the near term [9].

Industry Overview - The Zacks Medical – Biomedical and Genetics industry group ranks in the top 26% out of over 250 industries, indicating strong performance and potential for continued outperformance over the next 3 to 6 months [7] - The industry group has favorable metrics, with a PEG ratio of 1.57 and projected EPS growth of 13.18%, compared to the iShares S&P 500's PEG ratio of 2.12 and projected EPS growth of 6.87% [9] Company Highlights - Gilead Sciences (GILD) is a leading stock in the biomedical sector, known for its innovative medicines for life-threatening illnesses. It has a Zacks Rank of 2 (Buy) and has a trailing four-quarter average earnings surprise of 19.5% [11][12] - GILD reported fourth-quarter earnings of $1.90 per share, exceeding consensus estimates by 13.8%. The stock is trading at 14.5 times forward earnings and has increased over 23% in 2025, reaching a 52-week high [12][13] - Jazz Pharmaceuticals (JAZZ) is another strong performer in the same industry, holding a Zacks Rank of 1 (Strong Buy). The company focuses on neuroscience and oncology and has surpassed earnings estimates in three of the past four quarters [15][16] - JAZZ reported fourth-quarter earnings of $6.60 per share, a 14% surprise over consensus estimates. The stock trades at six times forward earnings, significantly below the industry average, and has advanced more than 11% this year [16][17][18] Investment Strategy - The Zacks Rank methodology helps identify stocks with positive earnings estimate revisions, which can lead to better investment outcomes. Stocks with a Zacks Rank of 3 or better and a positive Earnings ESP have produced positive surprises 70% of the time [20] - JAZZ has a Zacks Rank of 1 and an Earnings ESP of +3.6%, indicating potential for another earnings beat in the upcoming Q1 results [21]

Core Viewpoint - Lionsgate Studios Corp. (LION) has shown a significant price increase of 18.8% over the past four weeks, with a mean price target of $10.83 indicating a potential upside of 27.1% from the current trading price of $8.52 [1] Price Target Analysis - The average price target consists of three estimates ranging from a low of $8.50 to a high of $14, with a standard deviation of $2.84, suggesting variability in analyst predictions [2] - The lowest estimate indicates a slight decline of 0.2%, while the highest estimate suggests a substantial upside of 64.3% [2] - A low standard deviation indicates a strong agreement among analysts regarding the stock's price movement [7] Analyst Sentiment - Analysts have shown a positive trend in earnings estimate revisions for LION, which is a strong indicator of potential stock upside [4][9] - The Zacks Consensus Estimate for the current year has increased by 113.8% over the past month, reflecting a positive outlook from analysts [10] - LION holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11] Caution on Price Targets - Solely relying on price targets for investment decisions may not be prudent, as they can often mislead investors [3][5][8] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6]

Core Insights - Marvell Technology (MRVL) is expected to report quarterly earnings of $0.59 per share, a 28.3% increase year-over-year, with revenues projected at $1.8 billion, reflecting a 26.5% year-over-year growth [1] Earnings Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating analysts have collectively reassessed their initial estimates [1][2] Revenue Projections by End Market - Analysts project 'Net Revenue by end market- Data center' to be $1.37 billion, a significant increase of 78.6% from the previous year [4] - 'Net Revenue by end market- Carrier infrastructure' is estimated at $97.54 million, showing a decline of 42.6% year-over-year [4] - 'Net Revenue by end market- Automotive/industrial' is expected to reach $86.63 million, reflecting a 5.3% increase from the prior year [5] - The consensus for 'Net Revenue by end market- Consumer' stands at $82.37 million, indicating a decrease of 42.8% from the year-ago quarter [5] - 'Net Revenue by end market- Enterprise networking' is forecasted to be $172.49 million, representing a decline of 34.9% year-over-year [6] Stock Performance - Marvell shares have decreased by 20.6% over the past month, contrasting with a 2.4% decline in the Zacks S&P 500 composite [6] - With a Zacks Rank 2 (Buy), MRVL is anticipated to outperform the overall market in the near future [6]